Literature DB >> 12743679

Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats.

Ottavio Gandolfi1, Manuela Voltattorni, Renato Gaggi, Rossella Dall'Olio.   

Abstract

Antipsychotic drugs reportedly show a common property in facilitating glutamatergic transmission in rat cerebral cortex. Since the binding of the radiolabelled channel blocker [3H]-MK801 is generally considered an affordable index of N-methyl-d-aspartate (NMDA)-sensitive glutamate receptor activation, we examined the effects of clinically effective treatment (3 weeks, daily administration) of the atypical antipsychotic drug olanzapine (32 micromol/kg/5 ml) on the specific binding of [3H]-MK801 specific binding and on the strychnine-insensitive glycine sites (glycine B) in synaptic plasma membranes (SPM) prepared from the medial prefrontal cortex (mPFC) of rats sacrificed after different (24, 60, 120 h) washout periods. We studied also the effects of repeated olanzapine administration on [3H]-ketanserin binding to 5HT2A receptors to verify whether, consistent with previously reported paradoxical effects of repeated administration of 5HT2A antagonists, this drug decreases 5HT2A receptor density without changing the apparent affinity. Neither single nor repeated olanzapine administration changed the kinetic characteristics of [3H]-MK801 or [3H]-glycine specific binding. When rats were sacrificed 120 h after the last olanzapine administration, both single or repeated treatment had failed to change the kinetic characteristics of [3H]-ketanserin binding, while the apparent affinity of 5HT2A receptors was increased in animals sacrificed at shorter (60 h) washout periods. Owing to the long half-life of olanzapine (24 h), and since the drug concentrations in mPFC of rats sacrificed 60 h after a single olanzapine administration (about 50 nM) are high enough to induce changes in 5HT2A receptor affinity, it is concluded that this modification, probably unrelated to the therapeutic efficacy, could be due to some drug still present in the brain at the time of the sacrifice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743679     DOI: 10.1007/s00210-003-0761-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  47 in total

1.  Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.

Authors:  J T Noga; T M Hyde; M M Herman; C F Spurney; L B Bigelow; D R Weinberger; J E Kleinman
Journal:  Synapse       Date:  1997-11       Impact factor: 2.562

2.  Blockade of the serotonergic system counteracts the dizocilpine-induced changes in dopaminergic function.

Authors:  R Dall'Olio; O Gandolfi; R Gaggi
Journal:  Behav Pharmacol       Date:  2000-02       Impact factor: 2.293

3.  Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics.

Authors:  B P Sokolov
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

4.  Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine.

Authors:  I Ninan; S K Kulkarni
Journal:  Eur J Pharmacol       Date:  1999-02-26       Impact factor: 4.432

5.  Evaluation of the efficacy of antipsychotic attenuation of phencyclidine-disrupted prepulse inhibition in rats.

Authors:  J L Wiley; K L Kennedy
Journal:  J Neural Transm (Vienna)       Date:  2002-04       Impact factor: 3.575

6.  NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Authors:  A K Malhotra; D A Pinals; H Weingartner; K Sirocco; C D Missar; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1996-05       Impact factor: 7.853

7.  Modulatory role of dopamine on excitatory amino acid receptors.

Authors:  O Gandolfi; R Dall'Olio
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1996-05       Impact factor: 5.067

8.  Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone.

Authors:  D L Ceulemans; Y G Gelders; M L Hoppenbrouwers; A J Reyntjens; P A Janssen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs.

Authors:  M Kuoppamäki; E P Pälvimäki; J Hietala; E Syvälahti
Journal:  Neuropsychopharmacology       Date:  1995-10       Impact factor: 7.853

10.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

View more
  1 in total

1.  In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.

Authors:  Somayeh Jafari; Xu-Feng Huang; Jessica L Andrews; Francesca Fernandez-Enright
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.